Study guide

7.1 Naloxone & Opioid-Safety Laws in Utah

Utah MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC

1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline

2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel

2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel

3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment

3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement

4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing

4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records

5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards

6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration

6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs

7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program

8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah

8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security

9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database

9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)

10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products

10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales

11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery

11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients

12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs

12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards

13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation

13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits

7.1 Naloxone & Opioid-Safety Laws in Utah

Key Takeaways Explain This Topic AI

A Utah pharmacist may dispense an opiate antagonist without any other prescription under a physician's standing order issued under Utah Code § 26B-4-510.

Utah permits naloxone to be given to a person at increased risk of an opiate overdose, a family member, friend, or other person in a position to assist, or an overdose outreach provider (Utah Code §§ 26B-4-509, -510).

A pharmacy that dispenses naloxone under a standing order must report total doses and products annually to DOPL and the issuing physician by 15 days after December 31 (R156-17b-625).

Utah law since 2026 allows dispensing and good-faith administration of an expired opiate antagonist up to 24 months past its expiration date (Utah Code §§ 26B-4-509, -510).

A Utah prescriber must offer an opiate antagonist with an initial opiate prescription of 50 MME per day or more, or with a concurrent benzodiazepine, unless the supply is three days or less or is administered directly (Utah Code § 58-37-306(4)).

Last updated: September 2026

7.1 Naloxone & Opioid-Safety Laws in Utah

Blueprint item 2.5 covers "requirements for promoting quality and safety of public health." Utah's opiate-antagonist laws are in Title 26B, Chapter 4, §§ 26B-4-508 to -514 (formerly Title 26, Chapter 55), R156-17b-625 , DHHS's Utah Statewide Naloxone Standing Order , and DOPL's Utah Guidance for Naloxone under § 58-17b-627.

Two paths to dispense naloxone without an individual prescription

Pathway Authority Key features

Physician standing order § 26B-4-510; R156-17b-625; statewide standing order Issued by a physician (including a DHHS physician or local health department medical director). Recipients are limited to the categories below. Dispensers are identified by license number. The physician reviews dispensing practices at least annually . Dispensers keep records. DOPL approves the protocol by rule.

Pharmacist prescribing § 58-17b-627; R156-17b-627; Utah Guidance for Naloxone The pharmacist assesses eligibility, prescribes, and must personally train the patient before dispensing. Written materials cannot replace the consultation. PCP notification and 5-year retention apply (Section 6.3).

Participation is voluntary and creates no standard of care to prescribe or dispense (§ 26B-4-508).

Who may receive an opiate antagonist

Under §§ 26B-4-509(3) and 26B-4-510(3), naloxone may be prescribed or dispensed, without a prescriber-patient relationship , to:

an individual at increased risk of an opiate-related overdose;

a family member, friend, or other person in a position to assist that individual. The standing order lists examples, including people acting on behalf of law enforcement, DHHS, local health departments, treatment and recovery organizations, homeless service providers, naloxone-training organizations, harm-reduction programs, and schools; or

an overdose outreach provider , for furnishing to those individuals or for administering during an overdose.

The recipient need not be the at-risk person and need not bring any records. A worried parent may obtain naloxone for an adult child.

Products and quantities (standing order and DOPL guidance)

Nasal spray 4 mg/0.1 mL: one box of two devices. One spray in one nostril, and repeat with the second device in the other nostril after 2–3 minutes if there is no or minimal response. Call 911 if used.

Naloxone 1 mg/mL in 2-mL prefilled syringes with atomizers: two syringes with two atomizers, 1 mL in each nostril.

Auto-injector 2 mg/0.4 mL: one box of two, injected into the outer thigh.

0.4 mg/mL vials or prefilled syringes: two 1-mL doses with syringes for IM injection in the deltoid or thigh.

Dispense at least two doses to an individual, or an amount appropriate for an organization that will redistribute. Refills are allowed.

Required education

A provider who dispenses under these statutes must give written instruction on how to recognize an opiate overdose, how to respond (administer the antagonist and make sure the person gets additional medical care and evaluation as soon as possible), and the safety, efficacy, and risks of an expired antagonist (§ 26B-4-509(4)). DOPL's guidance also requires the pharmacist to cover:

  • the signs and symptoms of overdose;
  • calling 911 as soon as possible, and the possible need for rescue breathing;
  • how to use the specific product;
  • adverse reactions, including opioid withdrawal after administration;
  • storage conditions and temperature excursions;
  • expiration and disposal; and

information about substance use and behavioral health treatment, if applicable.

Expired opiate antagonists (2026)

An "expired opiate antagonist" is one no more than 24 months past its labeled expiration month and year. The statutes now authorize prescribing, dispensing, furnishing, and good-faith administration of such products, with education on their safety, efficacy, and risks (§§ 26B-4-509 to -511, amended 2026).

Records and reporting

Annual report (R156-17b-625): the PIC or a responsible corporate officer of each pharmacy that dispenses under a standing order must affirm compliance and report the total single doses dispensed and each product with its dose count to DOPL and to the issuing physician, no later than 15 days after December 31 . Chains may submit one combined report broken out by location. No report is needed if nothing was dispensed. The DHHS standing order directs reports through naloxone.utah.gov. Failing to report on time is unprofessional conduct (R156-17b-502(25)).

Records kept for audit (R156-17b-625(5)): recipient's name; product name, quantity, strength, and dosage quantity; the dispensing outlet; date; and the physician who issued the standing order.

Related opioid-safety provisions

Initial opiate prescriptions (§ 58-37-306). Before an initial opiate prescription, the prescriber must discuss addiction and overdose risks, the dangers of combining with alcohol and benzodiazepines, why the prescription is needed, alternatives, and other risks. This does not apply to active cancer treatment, hospice, or substance use disorder treatment. Since January 1, 2024 , the prescriber must offer an opiate antagonist when the initial opiate prescription is 50 MME/day or more , or when a benzodiazepine is also prescribed. The offer is not required if the drug is administered directly or the supply is three days or less . The patient does not have to accept it.

Pharmacy offer and warning duties (§ 58-37-112). When dispensing a Schedule II or III opiate, the pharmacy must put the warning "Caution: Opioid. Risk of overdose and addiction" on the container or lid. Since January 1, 2024, it must also offer to counsel on and offer to dispense an opiate antagonist when a single opioid prescription is 50 MME/day or more , or when an opioid and a benzodiazepine are dispensed to the patient within 30 days of each other. It must display DHHS's opioid pamphlet at the point of sale if one is available (Section 10.1).

Hospital and ED dispensing. A hospital pharmacy may dispense an opioid antagonist at discharge without the usual "Class A pharmacy unavailable" condition, and must accept wholesale acquisition cost as payment (§ 58-17b-610.6(2)(b)). ED prescribers may provide a naloxone kit (R156-17b-610.5(2)(b)).

Pharmacist IM administration of naloxone requires training and physician direction (§ 58-17b-625; Section 6.1).

Immunity and Good Samaritan protections

Administration: an overdose outreach provider, or a person other than a health care facility or provider, who administers an antagonist in good faith (including an expired one) to someone believed to be overdosing is immune from civil and criminal liability . A health care provider acting within the scope of their duties is not covered by this immunity (§ 26B-4-509(2)).

Prescribing and dispensing: a prescriber or dispenser acting in good faith under § 26B-4-509(3) is not liable for civil damages.

Reporting an overdose: a person who reports an overdose in good faith, gives the location, stays at the scene until responders arrive, cooperates, and whose offense arose from the same events has an affirmative defense to possession or use charges (§ 76-18-207(10), enacted 2026). The same conduct is a mitigating factor at sentencing for Utah controlled-substance offenses (§ 76-3-203.11). "Good faith" excludes calls made during execution of a search or arrest warrant.